Efficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China

So which of the 5 causes of the neuronal cascade of death is this treating? Don't know, you didn't do your research correctly.

Efficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China

Longfei Wu, MD¹; Haiqing Song, MD¹; Chi Zhang, MD²; et al Anxin Wang, PhD^3,4; Bowei Zhang, MD¹; Chiyu Xiong, MD⁵; Xianbo Zhuang, MD⁶; Yingzhuo Zang, MD⁷; Chenghao Li, MD⁸; Qi Fang, MD⁹; Chuanqiang Qu, MD¹⁰; Lihua Wang, MD¹¹; Mei Zhang, MD¹²; Hao Li, MD¹³; Xiaoli Wang, MD¹⁴; Yanan Li, MD¹⁵; Lei Xia, MD¹⁶; Zhigang Yao, MD¹⁷; Zhi Nie, MD¹⁸; Ying Gao, MD, PhD²; Xunming Ji, MD, PhD¹⁹

Author Affiliations Article Information

JAMA Netw Open. 2023;6(6):e2317574. doi:10.1001/jamanetworkopen.2023.17574

visual abstract icon

Visual

Abstract

Key Points

Question  Do Panax notoginseng saponins (Xuesaitong soft capsules) improve function in patients with ischemic stroke?

Findings  In this multicenter randomized clinical trial of 3072 patients with ischemic stroke, the proportion of patients achieving functional independence at 3 months with P notoginseng saponins was 89% vs 82% with placebo; the difference was statistically significant.

Meaning  These findings suggest that Panax notoginseng saponins enhance functional independence in patients with ischemic stroke.

Abstract

Importance  Preclinical and clinical studies have suggested the neuroprotective effect of Panax notoginseng saponins (Xuesaitong soft capsules). However, robust evidence in patients with ischemic stroke is lacking.

Objective  To assess the efficacy and safety of Xuesaitong soft capsules in patients with ischemic stroke.

Design, Setting, and Participants  This multicenter, double-blind, placebo-controlled randomized clinical trial was conducted at 67 tertiary health centers in China from July 1, 2018, to June 30, 2020. Included patients were aged 18 to 75 years with a diagnosis of ischemic stroke and a National Institutes of Health Stroke Scale score between 4 and 15.

Interventions  Eligible patients were randomly assigned within 14 days after symptom onset to receive either treatment with Xuesaitong soft capsules (120 mg orally twice daily) or placebo (120 mg orally twice daily) for 3 months.

Main Outcomes and Measures  The primary outcome was functional independence at 3 months, defined as a modified Rankin Scale score of 0 to 2.

Results  Among 3072 eligible patients with ischemic stroke who were randomized, 2966 (96.5%) were included in the modified intention-to-treat cohort (median [IQR] age, 62 [55-68] years; 1982 male [66.8%]). The number of patients who achieved functional independence at 3 months was 1328 (89.3%) in the Xuesaitong group and 1218 (82.4%) in the control group (odds ratio, 1.95; 95% CI, 1.56-2.44; P < .001). In the safety cohort, serious adverse events occurred in 15 of 1488 patients (1.0%) in the Xuesaitong group and 16 of 1482 (1.1%) in the control group (P = .85).

Conclusions and Relevance  In this randomized clinical trial, Xuesaitong soft capsules significantly increased the likelihood of functional independence at 3 months in patients with ischemic stroke, indicating that this may be a safe and effective alternative therapy to improve prognosis in this population.

Trial Registration  Chinese Clinical Trial Registry Identifier: ChiCTR1800016363